Lipocine's lpcn 1148 highlighted in the june 2025 edition of hepatology

Salt lake city , may 22, 2025 /prnewswire/ -- lipocine inc. (nasdaq: lpcn), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced that its development candidate lpcn 1148 for men with cirrhosis is featured in the "hepatology highlights" section of the june 2025 edition of hepatology. the article "lpcn 1148: rebuilding muscle memory in cirrhosis patients" was contributed by dr. kevin harris of the division of gastroenterology and hepatology, mayo clinic, minnesota.
LPCN Ratings Summary
LPCN Quant Ranking